View in EDS

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.

Saved in:
Bibliographic Details
Title: Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
Authors: Richardson PG; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: paul_richardson@dfci.harvard.edu., Perrot A; CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse, France., San-Miguel J; Clínica Universidad de Navarra, Navarra, CCUN, CIMA, IDISNA, CIBER-ONC, Pamplona, Spain., Beksac M; Department of Hematology, Ankara University, Ankara, Turkey., Spicka I; General Faculty Hospital, and First Faculty of Medicine, Charles University, Prague, Czech Republic., Leleu X; Service d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402, Poitiers Cedex, France., Schjesvold F; Oslo Myeloma Center, Department of Haematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway., Moreau P; Hematology Department, CHU Nantes, Nantes, France., Dimopoulos MA; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece., Huang JS; Department of Hematology, National Taiwan University Hospital, Taipei, Taiwan., Minarik J; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic., Cavo M; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy., Prince HM; Immunology and Molecular Oncology, Epworth Healthcare, University of Melbourne, Melbourne, VIC, Australia., Malinge L; Sanofi R&D, Vitry, France., Dubin F; Sanofi R&D, Vitry, France., van de Velde H; Sanofi R&D, Vitry, France., Anderson KC; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Source: The Lancet. Oncology [Lancet Oncol] 2022 Mar; Vol. 23 (3), pp. 416-427. Date of Electronic Publication: 2022 Feb 10.
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35151415
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Richardson+PG%22">Richardson PG</searchLink>; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: paul_richardson@dfci.harvard.edu.<br /><searchLink fieldCode="AU" term="%22Perrot+A%22">Perrot A</searchLink>; CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse, France.<br /><searchLink fieldCode="AU" term="%22San-Miguel+J%22">San-Miguel J</searchLink>; Clínica Universidad de Navarra, Navarra, CCUN, CIMA, IDISNA, CIBER-ONC, Pamplona, Spain.<br /><searchLink fieldCode="AU" term="%22Beksac+M%22">Beksac M</searchLink>; Department of Hematology, Ankara University, Ankara, Turkey.<br /><searchLink fieldCode="AU" term="%22Spicka+I%22">Spicka I</searchLink>; General Faculty Hospital, and First Faculty of Medicine, Charles University, Prague, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Leleu+X%22">Leleu X</searchLink>; Service d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402, Poitiers Cedex, France.<br /><searchLink fieldCode="AU" term="%22Schjesvold+F%22">Schjesvold F</searchLink>; Oslo Myeloma Center, Department of Haematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Moreau+P%22">Moreau P</searchLink>; Hematology Department, CHU Nantes, Nantes, France.<br /><searchLink fieldCode="AU" term="%22Dimopoulos+MA%22">Dimopoulos MA</searchLink>; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Huang+JS%22">Huang JS</searchLink>; Department of Hematology, National Taiwan University Hospital, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Minarik+J%22">Minarik J</searchLink>; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Cavo+M%22">Cavo M</searchLink>; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.<br /><searchLink fieldCode="AU" term="%22Prince+HM%22">Prince HM</searchLink>; Immunology and Molecular Oncology, Epworth Healthcare, University of Melbourne, Melbourne, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Malinge+L%22">Malinge L</searchLink>; Sanofi R&D, Vitry, France.<br /><searchLink fieldCode="AU" term="%22Dubin+F%22">Dubin F</searchLink>; Sanofi R&D, Vitry, France.<br /><searchLink fieldCode="AU" term="%22van+de+Velde+H%22">van de Velde H</searchLink>; Sanofi R&D, Vitry, France.<br /><searchLink fieldCode="AU" term="%22Anderson+KC%22">Anderson KC</searchLink>; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100957246%22">The Lancet. Oncology</searchLink> [Lancet Oncol] 2022 Mar; Vol. 23 (3), pp. 416-427. <i>Date of Electronic Publication: </i>2022 Feb 10.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lancet+Pub%2E+Group%22">Lancet Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100957246 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-5488 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214702045%22">14702045 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35151415
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S1470-2045(22)00019-5
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 416
    Titles:
      – TitleFull: Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Richardson PG
      – PersonEntity:
          Name:
            NameFull: Perrot A
      – PersonEntity:
          Name:
            NameFull: San-Miguel J
      – PersonEntity:
          Name:
            NameFull: Beksac M
      – PersonEntity:
          Name:
            NameFull: Spicka I
      – PersonEntity:
          Name:
            NameFull: Leleu X
      – PersonEntity:
          Name:
            NameFull: Schjesvold F
      – PersonEntity:
          Name:
            NameFull: Moreau P
      – PersonEntity:
          Name:
            NameFull: Dimopoulos MA
      – PersonEntity:
          Name:
            NameFull: Huang JS
      – PersonEntity:
          Name:
            NameFull: Minarik J
      – PersonEntity:
          Name:
            NameFull: Cavo M
      – PersonEntity:
          Name:
            NameFull: Prince HM
      – PersonEntity:
          Name:
            NameFull: Malinge L
      – PersonEntity:
          Name:
            NameFull: Dubin F
      – PersonEntity:
          Name:
            NameFull: van de Velde H
      – PersonEntity:
          Name:
            NameFull: Anderson KC
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: 2022 Mar
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1474-5488
          Numbering:
            – Type: volume
              Value: 23
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: The Lancet. Oncology
              Type: main
ResultId 1